Dogwood Therapeutics, Inc. Total Liabilities
Dogwood Therapeutics, Inc. total liabilities. Based on the latest financial reports, Dogwood Therapeutics, Inc. (DWTX) has total liabilities worth $14.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Dogwood Therapeutics, Inc. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Dogwood Therapeutics, Inc. (2018–2024)
Total liabilities of Dogwood Therapeutics, Inc. from 2018 to 2024. This chart illustrates how Dogwood Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Dogwood Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Dogwood Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Uniti SA
PA:ALUNT
|
France | €284.01 Million |
|
Nano Labs Ltd
NASDAQ:NA
|
USA | $351.10 Million |
|
Lotus Resources Ltd
AU:LOT
|
Australia | AU$43.91 Million |
|
Pyung Hwa Ind
KO:090080
|
Korea | ₩189.78 Billion |
|
Vivid Seats Inc
NASDAQ:SEAT
|
USA | $793.88 Million |
|
Khee San Bhd
KLSE:6203
|
Malaysia | RM6.09 Million |
|
Globrands Group Ltd
TA:GLRS
|
Israel | ILA476.20 Million |
|
Gome Telecom Equipment Co Ltd
SHG:600898
|
China | CN¥302.78 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Dogwood Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Dogwood Therapeutics, Inc. balance sheet assets.
Liquidity & Leverage Metrics
Dogwood Therapeutics, Inc. Total Liabilities Ratios Explained
Dogwood Therapeutics, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dogwood Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dogwood Therapeutics, Inc. (2018–2024)
The table below shows the annual total liabilities of Dogwood Therapeutics, Inc. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $30.03 Million | +8274.67% |
| 2023-12-31 | $358.55K | -65.63% |
| 2022-12-31 | $1.04 Million | -18.22% |
| 2021-12-31 | $1.28 Million | -16.73% |
| 2020-12-31 | $1.53 Million | -70.87% |
| 2019-12-31 | $5.26 Million | +296.46% |
| 2018-12-31 | $1.33 Million | -- |
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-… Read more